Drugging the undruggable RAS: Mission Possible?

Nature Reviews Drug Discovery

Volumn 13, Issue 11, 2014, Pages 828-851

  Cox, Adrienne D ^a   Fesik, Stephen W ^b   Kimmelman, Alec C ^c   Luo, Ji ^d   Der, Channing J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 8 [4 (2 HYDROXYETHOXY)CYCLOHEXYL] 6 (6 METHOXY 3 PYRIDINYL) 4 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 3 (2 AMINO 5 BENZOXAZOLYL) 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; APITOLISIB; AZD 2014; AZD 8055; BGT 226; BUPARLISIB; COPANLISIB; DACTOLISIB; DS 7423; EVEROLIMUS; GEDATOLISIB; LY 3023414; OMIPALISIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN INHIBITOR; RAPAMYCIN; RAS PROTEIN; RAS PROTEIN INHIBITOR; RIDAFOROLIMUS; SCH 53239; SCH 54292; SULINDAC; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VS 5584; VU 0460009; XL 765; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTINEOPLASTIC AGENT; ONCOPROTEIN;

BREAST CARCINOMA; CELL METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MUTANT; NONHUMAN; ONCOGENE RAS; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84908491115     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4389     Document Type: Review

References (231)

1. Cox, A. D. & Der, C. J. RAS history: The saga continues. Small GTPases 1, 2-27 (2010).
2. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
3. Thompson, H. US National Cancer Institute's new RAS project targets an old foe. Nature Med. 19, 949-950 (2013).
4. Berndt, N., Hamilton, A. D. & Sebti, S. M. Targeting protein prenylation for cancer therapy. Nature Rev. Cancer 11, 775-791 (2011).
5. Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).
6. Ji, H. et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-810 (2007).
7. Haigis, K. M. et al. Differential effects of oncogenic KRAS and NRAS on proliferation, differentiation and tumor progression in the colon. Nature Genet. 40, 600-608 (2008).
8. Brummelkamp, T. R., Bernards, R. & Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247 (2002).
9. Lim, K. H. & Counter, C. M. Reduction in the requirement of oncogenic RAS signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8, 381-392 (2005).
10. Singh, A. et al. A gene expression signature associated with "KRAS addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500 (2009).
11. Chin, L. et al. Essential role for oncogenic RAS in tumour maintenance. Nature 400, 468-472 (1999).
12. Collins, M. A. et al. Metastatic pancreatic cancer is dependent on oncogenic KRAS in mice. PLoS ONE 7, e49707 (2012).
13. Fisher, G. H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a KRAS transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249-3262 (2001).
14. Kwong, L. N. et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nature Med. 18, 1503-1510 (2012).
15. Ying, H. et al. Oncogenic KRAS maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670 (2012).
16. Bos, J. L., Rehmann, H. & Wittinghofer, A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 129, 865-877 (2007).
17. Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Dragging RAS back in the ring. Cancer Cell 25, 272-281 (2014).
18. Ahearn, I. M., Haigis, K., Bar-Sagi, D. & Philips, M. R. Regulating the regulator: post-translational modification of RAS. Nature Rev. Mol. Cell Biol. 13, 39-51 (2012).
19. Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J. & Brown, M. S. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 62, 81-88 (1990).
20. James, G. L., Goldstein, J. L. & Brown, M. S. Polylysine and CVIM sequences of KRASB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 270, 6221-6226 (1995).
21. Whyte, D. B. et al. K-and N-RAS are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459-14464 (1997).
22. Rowell, C. A., Kowalczyk, J. J., Lewis, M. D. & Garcia, A. M. Direct demonstration of geranylgeranylation and farnesylation of Ki-RAS in vivo. J. Biol. Chem. 272, 14093-14097 (1997).
23. Vigil, D., Cherfils, J., Rossman, K. L. & Der, C. J. RAS superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nature Rev. Cancer 10, 842-857 (2010).
24. Grant, B. J. et al. Novel allosteric sites on RAS for lead generation. PLoS ONE 6, e25711 (2011).
25. Buhrman, G. et al. Analysis of binding site hot spots on the surface of RAS GTPase. J. Mol. Biol. 413, 773-789 (2011).
26. Wang, W., Fang, G. & Rudolph, J. RAS inhibition via direct RAS binding-is there a path forward? Bioorg. Med. Chem. Lett. 22, 5766-5776 (2012).
27. Taveras, A. G. et al. RAS oncoprotein inhibitors: the discovery of potent, RAS nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg. Med. Chem. 5, 125-133 (1997).
28. Peri, F. et al. Design, synthesis and biological evaluation of sugar-derived RAS inhibitors. Chembiochem 6, 1839-1848 (2005).
29. Herrmann, C. et al. Sulindac sulfide inhibits RAS signaling. Oncogene 17, 1769-1776 (1998).
30. Waldmann, H. et al. Sulindac-derived RAS pathway inhibitors target the RAS-RAF interaction and downstream effectors in the RAS pathway. Angew. Chem. Int. Ed Engl. 43, 454-458 (2004).
31. Karaguni, I. M. et al. The new sulindac derivative IND 12 reverses RAS-induced cell transformation. Cancer Res. 62, 1718-1723 (2002).
32. Karaguni, I. M. et al. New indene-derivatives with anti-proliferative properties. Bioorg. Med. Chem. Lett. 12, 709-713 (2002).
33. Gonzalez-Perez, V. et al. Genetic and functional characterization of putative RAS/RAF interaction inhibitors in C. Elegans and mammalian cells. J. Mol. Signal. 5, 2 (2010).
34. Kato-Stankiewicz, J. et al. Inhibitors of RAS/RAF1 interaction identified by two-hybrid screening revert RAS-dependent transformation phenotypes in human cancer cells. Proc. Natl Acad. Sci. USA 99, 14398-14403 (2002).
35. Rosnizeck, I. C. et al. Stabilizing a weak binding state for effectors in the human RAS protein by cyclen complexes. Angew. Chem. Int. Ed Engl. 49, 3830-3833 (2010).
36. Patgiri, A., Yadav, K. K., Arora, P. S. & Bar-Sagi, D. An orthosteric inhibitor of the RAS-SOS interaction. Nature Chem. Biol. 7, 585-587 (2011).
37. Chang, Y. S. et al. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl Acad. Sci. USA 110, E3445-E3454 (2013).
38. Maurer, T. et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl Acad. Sci. USA 109, 5299-5304 (2012).
39. Sun, Q. et al. Discovery of small molecules that bind to KRAS and inhibit SOS-mediated activation. Angew. Chem. Int. Ed Engl. 51, 6140-6143 (2012).
40. Shima, F. et al. In silico discovery of small-molecule RAS inhibitors that display antitumor activity by blocking the RAS-effector interaction. Proc. Natl Acad. Sci. USA 110, 8182-8187 (2013).
41. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. KRAS (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551 (2013).
42. Chen, K. X. et al. A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors. J. Med. Chem. 55, 2089-2101 (2012).
43. Ward, R. A. et al. Structure-and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J. Med. Chem. 56, 7025-7048 (2013).
44. Lim, S. M. et al. Therapeutic targeting of oncogenic KRAS by a covalent catalytic site inhibitor. Angew. Chem. Int. Ed Engl. 53, 199-204 (2014).
45. Burns, M. C. et al. Approach for targeting RAS with small molecules that activate SOS-mediated nucleotide exchange. Proc. Natl Acad. Sci. USA 111, 3401-3406 (2014).
46. Chen, X., Makarewicz, J. M., Knauf, J. A., Johnson, L. K. & Fagin, J. A. Transformation by HrasG12V is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. Oncogene http://dx.doi.org/10.1038/onc.2013.489 (2013).
47. Liu, M. et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with KRAS-induced lung cancer. Proc. Natl Acad. Sci. USA 107, 6471-6476 (2010).
48. Marom, M. et al. Selective inhibition of RAS-dependent cell growth by farnesylthiosalisylic acid. J. Biol. Chem. 270, 22263-22270 (1995).
49. Gana-Weisz, M. et al. The RAS antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. Biochem. Biophys. Res. Commun. 239, 900-904 (1997).
50. Haklai, R. et al. Dislodgment and accelerated degradation of RAS. Biochemistry 37, 1306-1314 (1998).
51. Makovski, V., Haklai, R. & Kloog, Y. Farnesylthiosalicylic acid (salirasib) inhibits RHEB in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. Int. J. Cancer 130, 1420-1429 (2012).
52. McMahon, L. P., Yue, W., Santen, R. J. & Lawrence, J. C. Jr. Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-Raptor complex. Mol. Endocrinol. 19, 175-183 (2005).
53. Hanker, A. B. et al. Differential requirement of CAAX-mediated posttranslational processing for RHEB localization and signaling. Oncogene 29, 380-391 (2010).
54. Weisz, B. et al. A new functional RAS antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18, 2579-2588 (1999).
55. Haklai, R., Elad-Sfadia, G., Egozi, Y. & Kloog, Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother. Pharmacol. 61, 89-96 (2008).
56. Laheru, D. et al. Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest. New Drugs 30, 2391-2399 (2012).
57. Wahlstrom, A. M. et al. Rce1 deficiency accelerates the development of KRAS-induced myeloproliferative disease. Blood 109, 763-768 (2007).
58. Wahlstrom, A. M. et al. Inactivating Icmt ameliorates KRAS-induced myeloproliferative disease. Blood 112, 1357-1365 (2008).
59. Court, H. et al. Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J. Clin. Invest. 123, 4681-4694 (2013).
60. Majmudar, J. D. et al. Amide-modified prenylcysteine based ICMT inhibitors: structure-activity relationships, kinetic analysis and cellular characterization. Bioorg. Med. Chem. 20, 283-295 (2012).
61. Manandhar, S. P., Hildebrandt, E. R. & Schmidt, W. K. Small-molecule inhibitors of the RCE1P CAAX protease. J. Biomol. Screen 12, 983-993 (2007).
62. Winter-Vann, A. M. et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc. Natl Acad. Sci. USA 102, 4336-4341 (2005).
63. Chiu, V. K. et al. RAS signalling on the endoplasmic reticulum and the Golgi. Nature Cell Biol. 4, 343-350 (2002).
64. Cuiffo, B. & Ren, R. Palmitoylation of oncogenic NRAS is essential for leukemogenesis. Blood 115, 3598-3605 (2010).
65. Swarthout, J. T. et al. DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H-and N-RAS. J. Biol. Chem. 280, 31141-31148 (2005).
66. Goodwin, J. S. et al. Depalmitoylated RAS traffics to and from the Golgi complex via a nonvesicular pathway. J. Cell Biol. 170, 261-272 (2005).
67. Rocks, O. et al. The palmitoylation machinery is a spatially organizing system for peripheral membrane proteins. Cell 141, 458-471 (2010).
68. Rocks, O. et al. An acylation cycle regulates localization and activity of palmitoylated RAS isoforms. Science 307, 1746-1752 (2005).
69. Dekker, F. J. et al. Small-molecule inhibition of APT1 affects RAS localization and signaling. Nature Chem. Biol. 6, 449-456 (2010).
70. Resh, M. D. Targeting protein lipidation in disease. Trends Mol. Med. 18, 206-214 (2012).
71. Bivona, T. G. et al. PKC regulates a farnesyl-electrostatic switch on KRAS that promotes its association with BCL-XL on mitochondria and induces apoptosis. Mol. Cell 21, 481-493 (2006).
72. Sung, P. J. et al. Phosphorylated KRAS limits cell survival by blocking BCL-XL sensitization of inositol trisphosphate receptors. Proc. Natl Acad. Sci. USA 110, 20593-20598 (2013).
73. Kollar, P., Rajchard, J., Balounova, Z. & Pazourek, J. Marine natural products: bryostatins in preclinical and clinical studies. Pharm. Biol. 52, 237-242 (2013).
74. Barcelo, C. et al. Phosphorylation at Ser181 of oncogenic KRAS is required for tumor growth. Cancer Res. 74, 1190-1199 (2013).
75. Lim, K. H., Ancrile, B. B., Kashatus, D. F. & Counter, C. M. Tumour maintenance is mediated by eNOS. Nature 452, 646-649 (2008).
76. Lampson, B. L. et al. Targeting eNOS in pancreatic cancer. Cancer Res. 72, 4472-4482 (2012).
77. Zhang, H., Constantine, R., Frederick, J. M. & Baehr, W. The prenyl-binding protein PrBP/δ: a chaperone participating in intracellular trafficking. Vision Res. 75, 19-25 (2012).
78. Chandra, A. et al. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of RAS family proteins. Nature Cell Biol. 14, 148-158 (2012).
79. Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 497, 638-642 (2013).
80. Philips, M. R. RAS hitchhikes on PDE6δ. Nature Cell Biol. 14, 128-129 (2012).
81. Jura, N., Scotto-Lavino, E., Sobczyk, A. & Bar-Sagi, D. Differential modification of RAS proteins by ubiquitination. Mol. Cell 21, 679-687 (2006).
82. Sasaki, A. T. et al. Ubiquitination of KRAS enhances activation and facilitates binding to select downstream effectors. Sci. Signal 4, ra13 (2011).
83. Sumita, K. et al. Degradation of activated KRAS orthologue via KRAS-specific lysine residues is required for cytokinesis. J. Biol. Chem. 289, 3950-3959 (2014).
84. Yang, M. H. et al. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant KRAS. Mol. Cancer Res. 11, 1072-1077 (2013).
85. Baines, A. T., Xu, D. & Der, C. J. Inhibition of RAS for cancer treatment: the search continues. Future Med. Chem. 3, 1787-1808 (2011).
86. Blasco, R. B. et al. CRAF, but not BRAF, is essential for development of KRAS oncogene-driven non-small cell lung carcinoma. Cancer Cell 19, 652-663 (2011).
87. Collisson, E. A. et al. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2, 685-693 (2012).
88. Roskoski, R. Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol. Res. 66, 105-143 (2012).
89. Lyons, J. F., Wilhelm, S., Hibner, B. & Bollag, G. Discovery of a novel RAF kinase inhibitor. Endocr. Relat. Cancer 8, 219-225 (2001).
90. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
91. Lito, P., Rosen, N. & Solit, D. B. Tumor adaptation and resistance to RAF inhibitors. Nature Med. 19, 1401-1409 (2013).
92. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
93. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
94. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
95. Hall-Jackson, C. A. et al. Paradoxical activation of RAF by a novel RAF inhibitor. Chem. Biol. 6, 559-568 (1999).
96. Oberholzer, P. A. et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30, 316-321 (2012).
97. Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215 (2012).
98. Freeman, A. K., Ritt, D. A. & Morrison, D. K. Effects of RAF dimerization and its inhibition on normal and disease-associated RAF signaling. Mol. Cell 49, 751-758 (2013).
99. Gilmartin, A. G. et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989-1000 (2011).
100. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med. 14, 1351-1356 (2008).
101. Hatzivassiliou, G. et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers. Nature 501, 232-236 (2013).
102. Ishii, N. et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 73, 4050-4060 (2013).
103. Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321 (2012).
104. Little, A. S. et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal. 4, ra17 (2011).
105. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
106. Morris, E. J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742-750 (2013).
107. Gupta, S. et al. Binding of RAS to phosphoinositide 3-kinase p110 α is required for RAS-driven tumorigenesis in mice. Cell 129, 957-968 (2007).
108. Castellano, E. et al. Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 24, 617-630 (2013).
109. Ebi, H. et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest. 121, 4311-4321 (2011).
110. Britten, C. D. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother. Pharmacol. 71, 1395-1409 (2013).
111. Bodemann, B. O. & White, M. A. RAL GTPases and cancer: linchpin support of the tumorigenic platform. Nature Rev. Cancer 8, 133-140 (2008).
112. Neel, N. F. et al. The RALGEF-RAL effector signaling network: the road less traveled for anti-RAS drug discovery. Genes Cancer 2, 275-287 (2011).
113. Gonzalez-Garcia, A. et al. RALGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 7, 219-226 (2005).
114. Vigil, D. et al. Aberrant overexpression of the RGL2 RAL small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through RAL-dependent and RAL-independent mechanisms. J. Biol. Chem. 285, 34729-34740 (2010).
115. Lim, K. H. et al. Divergent roles for RALA and RALB in malignant growth of human pancreatic carcinoma cells. Curr. Biol. 16, 2385-2394 (2006).
116. Peschard, P. et al. Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis. Curr. Biol. 22, 2063-2068 (2012).
117. Wu, J. C. et al. Identification of V23RALA-Ser194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J. Biol. Chem. 280, 9013-9022 (2005).
118. Lim, K. H. et al. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol. Cell. Biol. 30, 508-523 (2010).
119. Wang, H. et al. Phosphorylation of RALB is important for bladder cancer cell growth and metastasis. Cancer Res. 70, 8760-8769 (2010).
120. Martin, T. D., Mitin, N., Cox, A. D., Yeh, J. J. & Der, C. J. Phosphorylation by protein kinase Cα regulates RALB small GTPase protein activation, subcellular localization, and effector utilization. J. Biol. Chem. 287, 14827-14836 (2012).
121. Chien, Y. et al. RALB GTPase-mediated activation of the IκB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127, 157-170 (2006).
122. Martin, T. D. et al. RAL and RHEB GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion. Mol. Cell 53, 209-220 (2014).
123. Malliri, A. et al. Mice deficient in the RAC activator TIAM1 are resistant to RAS-induced skin tumours. Nature 417, 867-871 (2002).
124. Lambert, J. M. et al. TIAM1 mediates RAS activation of RAC by a PI(3)K-independent mechanism. Nature Cell Biol. 4, 621-625 (2002).
125. Welch, H. C. et al. P-REX1, a PtdIns(3,4,5)P3-and Gβγ-regulated guanine-nucleotide exchange factor for RAC. Cell 108, 809-821 (2002).
126. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
127. Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genet. 44, 1006-1014 (2012).
128. Kissil, J. L. et al. Requirement for RAC1 in a KRAS induced lung cancer in the mouse. Cancer Res. 67, 8089-8094 (2007).
129. Heid, I. et al. Early requirement of RAC1 in a mouse model of pancreatic cancer. Gastroenterol 141, 719-730.e7 (2011).
130. Cardama, G. A. et al. Preclinical development of novel RAC1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines. Anticancer Agents Med. Chem. 14, 840-851 (2013).
131. Gao, Y., Dickerson, J. B., Guo, F., Zheng, J. & Zheng, Y. Rational design and characterization of a RAC GTPase-specific small molecule inhibitor. Proc. Natl Acad. Sci. USA 101, 7618-7623 (2004).
132. Chow, H. Y. et al. p21-activated kinase 1 is required for efficient tumor formation and progression in a RAS-mediated skin cancer model. Cancer Res. 72, 5966-5975 (2012).
133. Fritsch, R. et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 153, 1050-1063 (2013).
134. Chan, J. J. & Katan, M. PLCε and the RASSF family in tumour suppression and other functions. Adv. Biol. Regul. 53, 258-279 (2013).
135. Hartman, J. L. 4th, Garvik, B. & Hartwell, L. Principles for the buffering of genetic variation. Science 291, 1001-1004 (2001).
136. Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689-698 (2005).
137. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
138. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
139. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
140. Yu, B. & Luo, J. in Inhibitors of the RAS Superfamily G-proteins, Part B. (eds. Tamanoi, F. & Der, C. J.) 201-215 (Academic Press, 2013).
141. Cox, A. D. & Der, C. J. The dark side of RAS: regulation of apoptosis. Oncogene 22, 8999-9006 (2003).
142. Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149 642-655 (2012).
143. Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the RAS oncogene. Cell 137, 835-848 (2009).
144. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
145. Steckel, M. et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 22, 1227-1245 (2012).
146. Carretero, J. et al. Integrative genomic and proteomic analyses identify targets for LKB1-deficient metastatic lung tumors. Cancer Cell 17, 547-559 (2010).
147. Kim, H. S. et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155, 552-566 (2013).
148. Garraway, L. A. & Sellers, W. R. Lineage dependency and lineage-survival oncogenes in human cancer. Nature Rev. Cancer 6, 593-602 (2006).
149. Kapoor, A. et al. YAP1 activation enables bypass of oncogenic KRAS addiction in pancreatic cancer. Cell 158, 185-197 (2014).
150. Shao, D. D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171-184 (2014).
151. Cheung, H. W. et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl Acad. Sci. USA 108, 12372-12377 (2011).
152. Marcotte, R. et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2, 172-189 (2012).
153. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
154. Anderson, S. N., Towne, D. L., Burns, D. J. & Warrior, U. A high-throughput soft agar assay for identification of anticancer compound. J. Biomol. Screen 12, 938-945 (2007).
155. Meacham, C. E., Ho, E. E., Dubrovsky, E., Gertler, F. B. & Hemann, M. T. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nature Genet. 41, 1133-1137 (2009).
156. Zuber, J. et al. An integrated approach to dissecting oncogene addiction implicates a MYB-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 25, 1628-1640 (2011).
157. Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350 (2011).
158. Murugaesu, N. et al. An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. Cancer Discov. 4, 304-317 (2014).
159. Schramek, D. et al. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science 343, 309-313 (2014).
160. Zender, L. et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135, 852-864 (2008).
161. Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642-655 (2012).
162. Luo, T. et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc. Natl Acad. Sci. USA 109, 2860-2865 (2012).
163. Muvaffak, A. et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol. Cancer Res. 12, 1055-1066 (2014).
164. Zhu, Z. et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 4, 452-465 (2014).
165. Corcoran, R. B. et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23, 121-128 (2013).
166. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nature Protoc. 8, 2281-2308 (2013).
167. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
168. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
169. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
170. DeBerardinis, R. J. & Thompson, C. B. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148, 1132-1144 (2012).
171. Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441-464 (2011).
172. Stine, Z. E. & Dang, C. V. Stress eating and tuning out: cancer cells re-wire metabolism to counter stress. Crit. Rev. Biochem. Mol. Biol. 48, 609-619 (2013).
173. Levine, A. J. & Puzio-Kuter, A. M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344 (2010).
174. Racker, E., Resnick, R. J. & Feldman, R. Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. Proc. Natl Acad. Sci. USA 82, 3535-3538 (1985).
175. Wise, D. R. et al. MYC regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl Acad. Sci. USA 105, 18782-18787 (2008).
176. Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101-105 (2013).
177. White, E. Exploiting the bad eating habits of RAS-driven cancers. Genes Dev. 27, 2065-2071 (2013).
178. Yang, Z. & Klionsky, D. J. Eaten alive: a history of macroautophagy. Nature Cell Biol. 12, 814-822 (2010).
179. Kimmelman, A. C. The dynamic nature of autophagy in cancer. Genes Dev. 25, 1999-2010 (2011).
180. Mah, L. Y. & Ryan, K. M. Autophagy and cancer. Cold Spring Harb. Perspect. Biol. 4, a008821 (2012).
181. White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nature Rev. Cancer 12, 401-410 (2012).
182. Guo, J. Y. et al. Activated RAS requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 25, 460-470 (2011).
183. Guo, J. Y. et al. Autophagy suppresses progression of KRAS-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 27, 1447-1461 (2013).
184. Lock, R. et al. Autophagy facilitates glycolysis during RAS-mediated oncogenic transformation. Mol. Biol. Cell 22, 165-178 (2011).
185. Yang, S. et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25, 717-729 (2011).
186. Rao, S. et al. A dual role for autophagy in a murine model of lung cancer. Nature Commun. 5, 3056 (2014).
187. Rosenfeldt, M. T. et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 504, 296-300 (2013).
188. Yang, A. et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 4, 905-913 (2014).
189. Amaravadi, R. K. et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin. Cancer Res. 17, 654-666 (2011).
190. Mancias, J. D. & Kimmelman, A. C. Targeting autophagy addiction in cancer. Oncotarget 2, 1302-1306 (2011).
191. Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of RAS mutations in cancer. Cancer Res. 72, 2457-2467 (2012).
192. Yang, Z. & Klionsky, D. J. Mammalian autophagy: core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 22, 124-131 (2010).
193. Bar-Sagi, D. & Feramisco, J. R. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 233, 1061-1068 (1986).
194. Lim, J. P. & Gleeson, P. A. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol. Cell Biol. 89, 836-843 (2011).
195. Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in RAS-transformed cells. Nature 497, 633-637 (2013).
196. Kamphorst, J. J. et al. Hypoxic and RAS-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl Acad. Sci. USA 110, 8882-8887 (2013).
197. Yun, J. et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325, 1555-1559 (2009).
198. McCleland, M. L. et al. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin. Cancer Res. 19, 773-784 (2013).
199. Patra, K. C. et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24, 213-228 (2013).
200. Gaglio, D. et al. Oncogenic KRAS decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 7, 523 (2011).
201. Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for KRAS-mediated tumorigenicity. Proc. Natl Acad. Sci. USA 107, 8788-8793 (2010).
202. Shukla, K. et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J. Med. Chem. 55, 10551-10563 (2012).
203. Thornburg, J. M. et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 10, R84 (2008).
204. Nguyen, T., Nioi, P. & Pickett, C. B. The NRF2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284, 13291-13295 (2009).
205. DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109 (2011).
206. To, M. D. et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nature Genet. 40, 1240-1244 (2008).
207. Lampson, B. L. et al. Rare codons regulate KRAS oncogenesis. Curr. Biol. 23, 70-75 (2013).
208. Abubaker, J. et al. Prognostic significance of alterations in KRAS isoforms KRAS4A/4B and KRAS mutations in colorectal carcinoma. J. Pathol. 219, 435-445 (2009).
209. De Roock, W. et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812-1820 (2010).
210. Tejpar, S. et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J. Clin. Oncol. 30, 3570-3577 (2012).
211. Ihle, N. T. et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl Cancer Inst. 104, 228-239 (2012).
212. Zhang, Z. et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature Genet. 29, 25-33 (2001).
213. Bremner, R. & Balmain, A. Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 61, 407-417 (1990).
214. Li, H. et al. Growth inhibitory effect of wild-type KRAS2 gene on a colonic adenocarcinoma cell line. World J. Gastroenterol. 13, 934-938 (2007).
215. Qiu, W. et al. Disruption of p16 and activation of KRAS in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2, 862-873 (2011).
216. Lin, W. C. et al. HRAS forms dimers on membrane surfaces via a protein-protein interface. Proc. Natl Acad. Sci. USA 111, 2996-3001 (2014).
217. Xu, J. et al. Dominant role of oncogene dosage and absence of tumor suppressor activity in NRAS-driven hematopoietic transformation. Cancer Discov. 3, 993-1001 (2013).
218. Grabocka, E. et al. Wild-type H-and N-RAS promote mutant KRAS-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 25, 243-256 (2014).
219. Young, A., Lou, D. & McCormick, F. Oncogenic and wild-type RAS play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3, 112-123 (2013).
220. Vonderheide, R. H. & Nathanson, K. L. Immunotherapy at large: the road to personalized cancer vaccines. Nature Med. 19, 1098-1100 (2013).
221. Bayne, L. J. et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21, 822-835 (2012).
222. Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G. & Bar-Sagi, D. Oncogenic KRAS-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836-847 (2012).
223. Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G. & Sood, A. K. RNA interference in the clinic: challenges and future directions. Nature Rev. Cancer 11, 59-67 (2011).
224. Thompson, H. J. et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57, 267-271 (1997).
225. Sarthy, A. V. et al. Survivin depletion preferentially reduces the survival of activated KRAS-transformed cells. Mol. Cancer Ther. 6, 269-276 (2007).
226. Morgan-Lappe, S. E. et al. Identification of RAS-related nuclear protein, targeting protein for Xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res. 67, 4390-4398 (2007).
227. Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834 (2009).
228. Vicent, S. et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J. Clin. Invest. 120, 3940-3952 (2010).
229. Wang, Y. et al. Critical role for transcriptional repressor SNAIL2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 29, 4658-4670 (2010).
230. Singh, A. et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148, 639-650 (2012).
231. Cullis, J. et al. The RHOGEF GEF-H1 is required for oncogenic RAS signaling via KSR1. Cancer Cell 25, 181-195 (2014).